Since 17 samples of patients with wildtype OC and 26 samples of BRCA1 mutation carriers with OC came from one institution (tumorbank ovarian cancer (TOC) of the Charité, Medical University of Berlin), we performed a test for interaction in order to identify possible laboratory or sampling bias. Here, BRCA1 is linked to ovarian cancer.